SCHEMBL6498429

SCHEMBL6498429

O=C(NC1CC2CC1CN2)c1ccc(-c2ccccc2O)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.40
NPC1 O15118 4/20 0.40
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GAA P10253 2/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
MAPT P10636 3/20 0.39
HSD17B1 P14061 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPK1 P28482 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CASP3 P42574 1/20 0.37
RECQL P46063 1/20 0.37
SENP7 Q9BQF6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497808 0.88 ALDH1A1 (0.54) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6498308 0.88 RAB9A (0.53) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6486675 0.88 SLC9A1 (0.44) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6488977 0.88 ALDH1A1 (0.53) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6497797 0.86 ALDH1A1 (0.51) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6489856 0.85 ERCC5 (0.45) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6488018 0.84 ALDH1A1 (0.48) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6485912 0.83 ALDH1A1 (0.43) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6486920 0.82 ALDH1A1 (0.40) RAB9ANPC1LMNASMN1; SMN2HTT
SCHEMBL6496644 0.81 FAAH (0.46) RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 RAB9A 1437/4885NPC1 224/4885LMNA 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.